Valganciclovir proves its value in CMV prevention

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.608, 2010-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients

By Åsberg Anders Rollag Halvor Hartmann Anders

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1159-1166

Informa Healthcare

Access to resources Recommend Favorite

Valganciclovir: A Review of its Use in the Management of CMV Infection and Disease in Immunocompromised Patients

By Cvetković Risto S. Wellington Keri

Drugs, Vol. 65, Iss. 6, 2005-01 ,pp. : 859-878

Adis International

Access to resources Recommend Favorite

Targeted CMV prophylaxis with valganciclovir viable

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Targeted CMV prophylaxis with valganciclovir viable

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 314, 2001-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Valganciclovir: once-daily alternative to ganciclovir for CMV

Inpharma, Vol. 1, Iss. 1365, 2002-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite